Found 172 clinical trials
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic, Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic, Estrogen Receptor Positive, HER2 Negative Breast Cancer
- 378 views
- 23 Nov, 2020
- 1 location
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
- 150 views
- 23 Nov, 2020
- 1 location
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
- 332 views
- 08 Nov, 2020
- 1 location
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
CYP2D6 intermediate/poor metabolizers of premenopausal patients with estrogen receptor-positive early breast cancer.
- 28 views
- 21 Jan, 2021
- 18 locations
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
- 35 views
- 23 Jun, 2021
- 246 locations
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …
- 33 views
- 07 Nov, 2020
- 1 location
Exemestane Letrozole or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Researchers have been studying breast cancer to learn the best way to treat the disease. Chemotherapy (treatment with anti-cancer drugs) is commonly given before surgery to shrink breast tumors. Research has shown that reducing the amount of the hormone estrogen that gets to the cancer in postmenopausal women with hormone-dependent …
- 6 views
- 07 Nov, 2020
- 1 location
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or
- 0 views
- 24 Jan, 2021
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR) negative breast cancer. It is notable for the high level of epidermal growth factor receptor (EGFR
- 2 views
- 07 Nov, 2020
- 1 location
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The secondary objectives are to evaluate:
- 38 views
- 28 Mar, 2021
- 56 locations